JP2024531314A - 小児ｍｓを治療するためのオファツムマブ - Google Patents

小児ｍｓを治療するためのオファツムマブ Download PDF

Info

Publication number
JP2024531314A
JP2024531314A JP2024509123A JP2024509123A JP2024531314A JP 2024531314 A JP2024531314 A JP 2024531314A JP 2024509123 A JP2024509123 A JP 2024509123A JP 2024509123 A JP2024509123 A JP 2024509123A JP 2024531314 A JP2024531314 A JP 2024531314A
Authority
JP
Japan
Prior art keywords
ofatumumab
treatment
patient
use according
fingolimod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024509123A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024531314A5 (https=
Inventor
バガー，モルテン
グラハム，ゴードン
エイドリアン ヘリング，ディーター
メルシュヘムケ，マルチン
スー，ウェンディ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2024531314A publication Critical patent/JP2024531314A/ja
Publication of JP2024531314A5 publication Critical patent/JP2024531314A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024509123A 2021-08-16 2022-07-27 小児ｍｓを治療するためのオファツムマブ Pending JP2024531314A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163233524P 2021-08-16 2021-08-16
US63/233,524 2021-08-16
US202163254684P 2021-10-12 2021-10-12
US63/254,684 2021-10-12
EP21206466 2021-11-04
EP21206466.1 2021-11-04
PCT/EP2022/071132 WO2023020802A1 (en) 2021-08-16 2022-07-27 Ofatumumab for treating pediatric ms

Publications (2)

Publication Number Publication Date
JP2024531314A true JP2024531314A (ja) 2024-08-29
JP2024531314A5 JP2024531314A5 (https=) 2025-08-07

Family

ID=82940064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024509123A Pending JP2024531314A (ja) 2021-08-16 2022-07-27 小児ｍｓを治療するためのオファツムマブ

Country Status (7)

Country Link
US (1) US20240343821A1 (https=)
EP (1) EP4387999A1 (https=)
JP (1) JP2024531314A (https=)
KR (1) KR20240046200A (https=)
CA (1) CA3229704A1 (https=)
IL (1) IL310813A (https=)
WO (1) WO2023020802A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3733712T (lt) 2016-08-15 2023-09-11 Novartis Ag Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
EP4707302A2 (en) * 2020-04-09 2026-03-11 Novartis AG Ofatumumab for treating ms while maintaining serum igg

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients

Also Published As

Publication number Publication date
US20240343821A1 (en) 2024-10-17
KR20240046200A (ko) 2024-04-08
IL310813A (en) 2024-04-01
CA3229704A1 (en) 2023-02-23
WO2023020802A1 (en) 2023-02-23
EP4387999A1 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
JP2024531314A (ja) 小児ｍｓを治療するためのオファツムマブ
TW201521718A (zh) 低頻率格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之治療
EP3864053B1 (en) Treatment of rms by switching therapy
JP2026009900A (ja) 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ
CN117813328A (zh) 用于治疗儿童ms的奥法妥木单抗
RU2849464C1 (ru) Лечение rms путем смены терапии
HK40051003B (en) Treatment of rms by switching therapy
HK40051003A (en) Treatment of rms by switching therapy
US20240043545A1 (en) Methods and compositions for treatment of thyroid eye disease
US20260097063A1 (en) Anti-c5 antibody/c5 irna dosing regimens for treating c5-associated diseases
CN121843712A (zh) 用于治疗多发性硬化症的组合物和方法
TW202300523A (zh) 用於治療MS同時維持血清IgG之奧法木單抗(OFATUMUMAB)
AU2024357712A1 (en) Extended dosing regimens for anti-cd20 antibodies in the treatment of multiple sclerosis
JP2024516019A (ja) 抗ｂａｆｆｒ抗体を使用する全身性エリテマトーデスのための治療
BR122024017958A2 (pt) Usos de ofatumumab para tratamento de esclerose múltipla (em) enquanto mantém a igg sérica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250725

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250725